Injectable Leqembi permits weekly maintenance dosing of the Eisai and Biogen Alzheimer’s disease drug that may be done at a patient’s home. Other recent notable regulatory new include several rare disease drug approvals and narrower FDA nods for Covid-19 vaccines.
The post Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug appeared first on MedCity News.
